NEW Zealand’s PHARMAC has
confirmed it will fund MSD’s
melanoma drug pembrolizumab
(Keytruda) from 01 Sep, in the light
of new clinical evidence which has
given it the “confidence we needed
to progress the funding decision”.
“PHARMAC has been able to
adapt to an evolving evidence base
and changes in affordability that
have come with our negotiations
with MSD and an increase in the
medicines budget,” said PHARMAC
director of operations Sarah Fitt.
The deal will also see PHARMAC
fund a modified-release tablet form
of posaconazole (Noxafil) effective
01 Sep.
Fitt said the move “reflects the
flexibility of the PHARMAC model,
while allowing us to make the high quality
decisions New Zealanders
expect.”The above article was sent to subscribers in Pharmacy Daily's issue from 03 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Aug 16
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.